SML0124
Rasagiline mesylate
≥98% (HPLC), MAO B inhibitor, powder
Synonym(s):
(1R)-2,3-Dihydro-N-2-propynl-1H-inden-1-amine methanesulfonate, N-Propargyl-1(R)-aminoindan methanesulfonate, TVP-1012
Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C12H13N · CH4O3S
CAS Number:
Molecular Weight:
267.34
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
Product Name
Rasagiline mesylate, ≥98% (HPLC)
SMILES string
CS(O)(=O)=O.C#CCN[C@@H]1CCc2ccccc12
InChI
1S/C12H13N.CH4O3S/c1-2-9-13-12-8-7-10-5-3-4-6-11(10)12;1-5(2,3)4/h1,3-6,12-13H,7-9H2;1H3,(H,2,3,4)/t12-;/m1./s1
InChI key
JDBJJCWRXSVHOQ-UTONKHPSSA-N
assay
≥98% (HPLC)
form
powder
optical activity
[α]/D +15 to +28°, c = 0.6 mg/mL in H2O
storage condition
desiccated
color
white to tan
solubility
H2O: ≥20 mg/mL
storage temp.
2-8°C
Quality Level
Gene Information
human ... MAOB(4129)
Related Categories
Application
Rasagiline mesylate has been used:
- to test its neuroprotective effects in retinitis pigmentosa (RP) by apoptosis regulator, Bax/Bcl-2 modulation
- as monoamine oxidase-B inhibitor in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced mouse model
- as an anti-parkinsonian agent to test its rescue functionality in 6-hydroxydopamine-lesioned zebrafish larvae towards bradykinetic and dyskinetic-like behavior
Rasagiline mesylate may be used in MAO type B-mediated cell signaling studies.
Biochem/physiol Actions
Anti-Parkinson drug; MAO B Inhibitor; anti-apoptotic; neuroprotectant
Rasagiline mesylate is an effective therapeutic option in early stages of Parkinson′s disease. It improves the motor fluctuations in levodopa-treated patients and may be a useful adjunct to such patients. It has neuroprotective effects and increases the survival of dopaminergic neurons.
Rasagiline mesylate is an irreversible inhibitor of monoamine oxidase selective for MAO type B over type A by a factor of fourteen. It has anti-apoptotic and neuroprotectant activity and has been used as a treatment for Parkinson′s disease.
Features and Benefits
This compound is featured on the Dopamine and Norepinephrine Metabolism and Histamine Synthesis and Metabolism pages of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
J P Finberg et al.
Neuroreport, 9(4), 703-707 (1998-04-29)
Both deprenyl and rasagiline (R(+)-N-propargyl-1-aminoindane mesylate), at a concentration of 1-10 microM, increased survival in vitro of rat E14 mesencephalic dopaminergic neurons that had been primed with 10% serum for 12 h (p < 0.05). Rasagiline, but not deprenyl, also
J M Rabey et al.
Clinical neuropharmacology, 23(6), 324-330 (2001-09-29)
Rasagiline mesylate (TVP-1012) is a potent, selective, non-reversible MAO-B inhibitor, without the tyramine-potentiating effect and with neuroprotective activities. The benefit of rasagiline as monotherapy in patients with early Parkinson's disease (PD) has already been reported. To evaluate the safety, tolerability
Rita L Vaz et al.
Pharmacology, biochemistry, and behavior, 189, 172828-172828 (2019-12-01)
Parkinson's disease (PD) is known as a movement disorder due to characteristic motor features. Existing therapies for PD are only symptomatic, and their efficacy decreases as disease progresses. Zebrafish, a vertebrate in which parkinsonism has been modelled, offers unique features
Selegiline recovers synaptic plasticity in the medial prefrontal cortex and improves corresponding depression-like behavior in a mouse model of Parkinson's disease
Okano M, et al.
Frontiers in Behavioral Neuroscience, 13, 176-176 (2019)
Dhaval R Kalaria et al.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 127, 204-212 (2018-02-27)
Effective treatment of Parkinson's disease (PD) involves administration of therapeutic agents with complementary mechanisms of action in order to replenish, sustain or substitute endogenous dopamine. The objective of this study was to investigate anodal co-iontophoresis of pramipexole (PRAM; dopamine agonist)
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service